DENVER – Santen announced the U.S. availability of Verkazia for the treatment of vernal keratoconjunctivitis in children and adults during the ARVO meeting.
The cyclosporine ophthalmic suspension 0.1%, a topical immunomodulator, is formulated in a way that it stays longer on the ocular surface, Santen’s senior vice president and global head of ophthalmic innovation center, Reza Haque, MD, PhD, told Healio.
Previously, the only treatment for vernal keratoconjunctivitis was a topical steroid, which cannot be taken long-term due to associated risks, Haque said. Verkazia has a “steroid